Predictors of recurrence in stage I (T1N0M0) XXXX .

@entity1 @entity1137 @entity3079 @entity0 @entity5 @entity189 @entity204
A ten-year follow-up study of 382 @entity1 with Stage I (T1N0M0) @entity0 revealed @entity204 due to @entity5 in 16% of the @entity1 . Among 134 @entity1 (35%) with a primary @entity5 1.0 cm or less in diameter (Group A), 7% had recurrences and 5% died of @entity0 . Recurrences were observed in 21% of the 248 @entity1 with a @entity5 1.1-2.0 cm in diameter (Group B), and 15% died of disease. These differences in recurrence and mortality rates were statistically significant. All recurrences were due to infiltrating @entity1137 which accounted for 91% of the 382 @entity189 . Most strongly linked to recurrence was the finding of @entity5 emboli in lymphatics of the breast. This was found in 23 Group B @entity1 and ten of them (43%) died of disease. No recurrences were observed among the seven Group A @entity1 with lymphatic emboli. Other features associated with a significantly increased risk of recurrence were poorly differentiated @entity189 , marked @entity5 , and menarche before age 12 years or after age 14 years. No combination of variables proved to identify a subset of @entity1 with an especially increased or low risk of recurrence. Stage I @entity1 with @entity5 in the breast surrounding a @entity189 1.1-2.0 cm in diameter have a sufficient risk for recurrence to warrant consideration of adjuvant systemic therapy. A very low risk of recurrence was observed for the following: any @entity5 1.0 cm or smaller; and tubular, medullary or @entity3079 up to 2.0 cm.
